Background: Mucopolysaccharidoses (MPS) are lysosomal storage disorders caused by deficiencies in enzymes involved in glycosaminoglycan catabolism. Progressive tissue accumulation results in multisystem disease, with cardiac valve involvement being frequent and clinically relevant. We describe the cardiac phenotype and longitudinal evolution of six pediatric patients with MPS followed at a reference center for inherited metabolic diseases.
Case Presentation Summary: Patient 1 (MPS I), diagnosed at 3 years, had mitral valve thickening and mild mitral regurgitation (MR), which remained essentially stable during 4 years of enzyme replacement therapy (ERT). Patient 2 (MPS II), diagnosed at 2 years, initially had dysplastic but functionally normal mitral and aortic valves; over 5.5 years, mild MR and eccentric aortic regurgitation (AR) developed, together with PR-interval prolongation. Patient 3 (MPS I) underwent hematopoietic stem cell transplantation (HSCT) at 2 years, after characteristic echocardiographic findings contributed to the diagnosis. Over 15 years, aortic valve dysplasia progressed to moderate AR, and the mitral valve became myxomatous, with moderate MR and restricted opening, prompting medical therapy. ECG showed first-degree atrioventricular block. Patient 4 (MPS VI), diagnosed at 7 years, developed progressive mitral and aortic valve thickening over 8 years, evolving to mild mitral stenosis and moderate AR, treated with furosemide and captopril alongside ERT. Patient 5 (MPS III), diagnosed at 3 years, had a normal baseline echocardiogram but developed moderate AR without valve thickening after 11 years; ERT was not indicated for this subtype. Patient 6 (MPS VII), diagnosed at 3 years, showed mild mitral and aortic valve thickening that progressed over 11 years to mild late-systolic MR and mild AR while receiving ERT.
Learning Points Discussion: This series illustrates the heterogeneity of cardiac involvement across MPS subtypes, ranging from stable mild valvulopathy (MPS I) to progressive multivalvular disease requiring pharmacological therapy (MPS I after HSCT and MPS VI). Mitral and aortic valve thickening, often with dysplastic or myxomatous features, was the most consistent finding, with regurgitation predominating over stenosis. Notably, one patient's MPS diagnosis was prompted by echocardiographic findings, highlighting the importance of considering a storage disorder in unexplained pediatric valvulopathy. Conduction abnormalities were uncommon but present in two patients. These cases reinforce the need for systematic serial echocardiographic surveillance throughout the disease course, regardless of MPS subtype or therapeutic modality, to guide timely pharmacological or surgical intervention.

